Literature DB >> 15388482

Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Jackie K Imai1, Gaurav Singh, Karl V Clemons, David A Stevens.   

Abstract

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15388482      PMCID： PMC521895          DOI： 10.1128/AAC.48.10.4063-4066.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Worst-rank score analysis with informatively missing observations in clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1999-10

Review 2.  New targets and delivery systems for antifungal therapy.

Authors:  T J Walsh; M A Viviani; E Arathoon; C Chiou; M Ghannoum; A H Groll; F C Odds
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

Review 3.  New investigational antifungal agents for treating invasive fungal infections.

Authors:  M A Hossain; M A Ghannoum
Journal:  Expert Opin Investig Drugs       Date:  2000-08       Impact factor: 6.206

4.  In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; F Persat; M F Monier; M A Piens; Ebga Network
Journal:  J Med Microbiol       Date:  1999-12       Impact factor: 2.472

5.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

Authors:  D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

6.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Authors:  G K Abruzzo; C J Gill; A M Flattery; L Kong; C Leighton; J G Smith; V B Pikounis; K Bartizal; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

9.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

10.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191
View more
  10 in total

1.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

3.  Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.

Authors:  Gaurav Singh; Jackie Imai; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 5.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

6.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 7.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.

Authors:  Guillermo Garcia-Effron; Amanda Dilger; Laura Alcazar-Fuoli; Steven Park; Emilia Mellado; David S Perlin
Journal:  J Clin Microbiol       Date:  2008-01-30       Impact factor: 5.948

9.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

10.  Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.

Authors:  Frédéric-Antoine Dauchy; Mélanie Bonhivers; Nicolas Landrein; Denis Dacheux; Pierrette Courtois; Florian Lauruol; Sylvie Daulouède; Philippe Vincendeau; Derrick R Robinson
Journal:  PLoS Negl Trop Dis       Date:  2016-11-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.